Patent ID: 8030275

Claim:
A method for reducing body weight in a mammal comprising administering to a human patient in need thereof: (a) an isolated polypeptide comprising: (i) the amino acid sequence of SEQ ID NO: 2; (ii) the amino acid sequence of SEQ ID NO: 5; (iii) the amino acid sequence of SEQ ID NO: 2, further comprising an amino-terminal methionine; or (iv) the amino acid sequence of SEQ ID NO: 5, further comprising an amino-terminal methionine; (b) an isolated polypeptide comprising an amino acid sequence that is encoded by: (i) the nucleotide sequence of SEQ ID NO: 1; (ii) the nucleotide sequence of the DNA insert in ATCC Deposit No. PTA-626; (iii) a nucleotide sequence encoding the polypeptide of SEQ ID NO: 2; or (iv) a nucleotide sequence encoding the polypeptide of SEQ ID NO: 5; (c) a pharmaceutical composition comprising an isolated polypeptide comprising: (i) the amino acid sequence of SEQ ID NO: 2; (ii) the amino acid sequence of SEQ ID NO: 5; (iii) the amino acid sequence of SEQ ID NO: 2, further comprising an amino-terminal methionine; or (iv) the amino acid sequence of SEQ ID NO: 5, further comprising an amino-terminal methionine; and a pharmaceutically acceptable formulation agent; or (d) a pharmaceutical composition comprising an isolated polypeptide comprising an amino acid sequence that is encoded by: (i) the nucleotide sequence of SEQ ID NO: 1; (ii) the nucleotide sequence of the DNA insert in ATCC Deposit No. PTA-626; (iii) a nucleotide sequence encoding the polypeptide of SEQ ID NO: 2; or (iv) a nucleotide sequence encoding the polypeptide of SEQ ID NO: 5; and a pharmaceutically acceptable formulation agent.